A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19

Authors

Manu Shankar-Hari, The University of Edinburgh
Kenneth E. Remy, Washington University School of Medicine in St. Louis
Jane Blood, Washington University School of Medicine in St. Louis
Andrew H. Walton, Washington University School of Medicine in St. Louis
Teresa Blood, Washington University School of Medicine in St. Louis
Richard Hotchkiss, Washington University School of Medicine in St. Louis
et al.

Journal

JCI Insight

Publication Date

2-4-2025

Volume

10

Issue

6

First Page

e189150

Document Type

Open Access Publication

DOI

10.1172/jci.insight.189150

Rights and Permissions

Shankar-Hari M, Francois B, Remy KE, Gutierrez C, Pastores S, Daix T, Jeannet R, Blood J, Walton AH, Salomao R, Auzinger G, Striker D, Martin RS, Anand NJ, Bosanquet J, Blood T, Brakenridge S, Moldawer LL, Vachharajani V, Yee C, Dal-Pizzol F, Morre M, Berbille F, van den Brink M, Hotchkiss R. A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19. JCI Insight. 2025 Feb 4;10(6):e189150. doi: 10.1172/jci.insight.189150. © 2025, Shankar-Hari et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Recommended Citation

Shankar-Hari, Manu; Remy, Kenneth E.; Blood, Jane; Walton, Andrew H.; Blood, Teresa; Hotchkiss, Richard; and et al., "A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19." JCI Insight. 10, 6. e189150 (2025).
https://digitalcommons.wustl.edu/oa_4/5208

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.